Omnipod 5 Real-World Evidence Data: A Deep Dive

Hosted by Nancy Hanna

The guest on this episode has an ongoing commercial relationship with Insulet, and Insulet has paid a fee for their participation in this podcast.

Recorded live at the ADA Conference in Orlando, Florida. Nancy Hanna is joined by Dr. Greg Forlenza who is an Endocrinologist at the University of Colorado School of Medicine – Barbara Davis Center. Dr. Forlenza is the lead author of a publication in Diabetes Technology & Therapeutics in which the use of the Omnipod 5 Automated Insulin Delivery System was analyzed in almost 70,000 people with type 1 diabetes.

Nancy and Dr. Forlenza discuss the relevance of real-world evidence from a diverse group of patients and how that translates into actual practice. Learn how Omnipod 5 has performed in real-world settings, and why having this data can help personalize diabetes care by understanding how different patient demographics can benefit from tubeless AID technology.

Time stamps

3:02 – Hear about the 250K patient years of real-world data from the Omnipod 5 All-Patient Database and how it compares to the cross over trial that resulted in FDA approval
13:23 – Learn how the Omnipod 5 real-world evidence data is unique from other AID real world evidence
15:55 – What does the data say about the benefits of Omnipod 5 for Medicare and Medicaid patients?

 

See more episodes
This podcast provides general information and discussions about health and related subjects. This information and other content provided in this podcast, or in any linked materials, are not intended and should not be construed as medical advice, nor is the information a substitute for professional medical expertise or treatment. If you or any other person has a medical concern, you should consult your health care provider or seek other professional medical treatment. Never disregard professional medical advice or delay in seeking it because of something that you have heard in this podcast or read in any linked materials. The opinions and views expressed on this podcast and website have no relation to those of any academic, hospital, health practice or other institution.

Please consult the Omnipod® 5 Automated Insulin Delivery System User Guide for more information.

The Omnipod 5 Automated Insulin Delivery System is a single hormone insulin delivery system intended to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in persons aged 2 and older & type 2 diabetes in persons aged 18 years and older. The Omnipod 5 System is intended for single patient use. The Omnipod 5 System is indicated for use with NovoLog®, Humalog®, and Admelog®. Refer to the Omnipod 5 Automated Insulin Delivery System User Guide and www.omnipod.com/safety for complete safety information including indications, contraindications, warnings, cautions, and instructions. Warning: DO NOT use SmartAdjust technology for individuals under 2 years of age or use less than 5 U of insulin per day. DO NOT start to use the Omnipod 5 System or change settings without adequate training and guidance from a healthcare provider. Initiating and adjusting settings incorrectly can result in over-delivery or under-delivery of insulin, which could lead to hypoglycemia or hyperglycemia.